Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 531

2.

Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment.

Ravn P, Christensen JO, Baumann M, Clemmesen B.

Bone. 1998 May;22(5):559-64.

PMID:
9600792
[PubMed - indexed for MEDLINE]
3.

Bisphosphonates for prevention of postmenopausal osteoporosis.

Ravn P.

Dan Med Bull. 2002 Feb;49(1):1-18. Review.

PMID:
11894721
[PubMed - indexed for MEDLINE]
4.

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.

McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH 3rd, Ensrud KE, Burdeska A, Mills T; Oral Ibandronate Study Group.

J Bone Miner Res. 2004 Jan;19(1):11-8.

PMID:
14753731
[PubMed - indexed for MEDLINE]
5.

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.

Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schöter KH.

Am J Med. 1997 Oct;103(4):298-307.

PMID:
9382122
[PubMed - indexed for MEDLINE]
6.

Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.

Stakkestad JA, Benevolenskaya LI, Stepan JJ, Skag A, Nordby A, Oefjord E, Burdeska A, Jonkanski I, Mahoney P; Ibandronate Intravenous Study Group.

Ann Rheum Dis. 2003 Oct;62(10):969-75.

PMID:
12972476
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Oral weekly ibandronate prevents bone loss in postmenopausal women.

Tankó LB, Felsenberg D, Czerwiński E, Burdeska A, Jonkanski I, Hughes C, Christiansen C; Oral Ibandronate Group.

J Intern Med. 2003 Aug;254(2):159-67.

PMID:
12859697
[PubMed - indexed for MEDLINE]
8.

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE).

J Bone Miner Res. 2004 Aug;19(8):1241-9. Epub 2004 Mar 29.

PMID:
15231010
[PubMed - indexed for MEDLINE]
9.

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.

McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD.

Bone. 2009 Mar;44(3):418-22. doi: 10.1016/j.bone.2008.09.011. Epub 2008 Oct 7.

PMID:
18950736
[PubMed - indexed for MEDLINE]
10.

Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.

Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A, et al.

Bone. 1995 Oct;17(4):383-90.

PMID:
8573412
[PubMed - indexed for MEDLINE]
11.

Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis.

Schlosser K, Scigalla P.

Scand J Clin Lab Invest Suppl. 1997;227:21-8.

PMID:
9127465
[PubMed - indexed for MEDLINE]
12.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
[PubMed - indexed for MEDLINE]
13.
14.

Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.

Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR.

J Rheumatol. 2008 Mar;35(3):488-97. Epub 2008 Feb 1.

PMID:
18260172
[PubMed - indexed for MEDLINE]
15.

Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.

Li M, Xing XP, Zhang ZL, Liu JL, Zhang ZL, Liu DG, Xia WB, Meng XW.

J Bone Miner Metab. 2010 May;28(3):299-305. doi: 10.1007/s00774-009-0126-y. Epub 2009 Oct 24.

PMID:
19855926
[PubMed - indexed for MEDLINE]
16.

Efficacy and safety of monthly ibandronate in men with low bone density.

Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.

Bone. 2010 Apr;46(4):970-6. doi: 10.1016/j.bone.2009.12.034. Epub 2010 Jan 6.

PMID:
20060082
[PubMed - indexed for MEDLINE]
17.

Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.

Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.

J Bone Miner Res. 1998 Sep;13(9):1431-8.

PMID:
9738515
[PubMed - indexed for MEDLINE]
18.
19.

Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.

Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM.

Arthritis Rheum. 2006 Jun;54(6):1838-46.

PMID:
16729277
[PubMed - indexed for MEDLINE]
Free Article
20.

Efficacy and safety of ibandronate given by intravenous injection once every 3 months.

Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, Coutant K, Schimmer RC, Delmas PD.

Bone. 2004 May;34(5):881-9.

PMID:
15121020
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk